Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Therefore, in this review we detail the direct and indirect molecular mechanisms by which incretin receptor agonists inhibit fibrotic signalling pathways, and critically appraise the evidence for their preclinical and clinical efficacy in fibrotic disorders across diverse tissues, including the liver, heart, kidney, lung, and joints (Table 1
This guide provides evidence-based recommendations for patients and clinicians navigating this common clinical scenario
10.1016/j.phrs.2019.104584 394
The variables selected in random forest differed depending on the model
Bioinformatics 38 , 34773480 (2022)
US$ 21.36
(mh=icTkswsVApU1i-RO)4.jpg)
US$ 28.53
(mh=NgIwOtqdVdkR3PFm)11.jpg)
US$ 27.18
US$ 23.74
US$ 20.13
